Moberg Pharma’s report for the second quarter to be published on August 7 - Invitation to teleconference
STOCKHOLM, July 30th, 2018 – On August 7th 2018, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its interim report for January - June 2018. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
The teleconference will be hosted by Moberg Pharmas’s CEO Peter Wolpert and VP Finance Mark Beveridge. The presentation will be held in English.
Date: May 8th, 2018
Time: 3:00 pm (CET)
To participate in the conference, please dial in on any number below before the start of the call:
SE: +46 8 505 564 53
US: +1 646 502 51 16
The quarterly report and other information material will be made public on:
For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 707 35 71 35, US phone: +1 908 432 22 03, E-mail: email@example.com
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: firstname.lastname@example.org
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ.) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis, phase 3 studies ongoing) and BUPI (pain management in oral mucositis, preparations for phase 3 studies ongoing). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).